Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.
OXFORD, England, April 26, 2023 /PRNewswire/ -- Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis. The platform, EchoGo Amyloidosis, uses artificial intelligence to analyse echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart. The novel technology is designed to address the unmet need for earlier diagnosis of amyloidosis patients, which otherwise may go unnoticed until the disease has advanced, delaying treatment, and adversely impacting patient outcomes. "While treatments exist to help slow or halt the progression of cardiac Amyloidosis, underdiagnosis in the early stages of disease is a huge challenge," said Najat Khan, Ph.D., Chief Data Science Officer and Global Head, Strategy & Operations at Janssen Research & Development, LLC. "When applied to routine tests like echocardiograms, artificial intelligence is demonstrating exciting potential to help facilitate earlier disease detection – with the goal of connecting patients with treatment sooner and, ultimately, driving better health outcomes." For more information, visit: www.ultromics.com About Ultromics: Ultromics is a pioneer in advanced heart failure detection. The ground-breaking platform, EchoGo ®, is transforming the way heart failure is diagnosed using artificial intelligence and cardiac ultrasound as a modality. The technology empowers clinicians to make precise, efficient, and accurate assessments of heart failure, leveraging the largest known heart disease outcomes dataset in echocardiography, accurately interpreting echocardiograms and predicting cardiac outcomes. The technology has been built in collaboration with Mayo Clinic and NHS England, and has over $50 million raised capital to support continued innovation with the likes of Blue Venture Fund, Optum Ventures, Oxford Science Enterprises, and GV. They are backed by the largest US health insurance firms with 4 FDA clearances. Ultromics' mission is to stop heart failure in its tracks with its precision detection platform. https://www.ultromics.com Media contacts: Sarah Jackson Photo - https://mma.prnewswire.com/media/2063538/Ultromics_ECG.jpg
SOURCE Ultromics |